Stockreport

MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026 [Yahoo! Finance]

MapLight Therapeutics, Inc.  (MPLT) 
PDF expected timing of topline results for its ongoing Phase 2 ZEPHYR and IRIS clinical studies, which are progressing ahead of schedule. The company's Phase 2 ZEPHYR tria [Read more]